URGENT: The COVID-19 epidemic is severely impacting the progress of ALS research at the ALS Therapy Development Institute. If you are able to give, will you please provide an immediate gift to fund our lab?



Talampanel may protect motor nerves from further deterioration by reducing glutamate levels in the brain and spinal cord. An AMPA glutamate receptor antagonist, talampanel is thought to prevent glutamate from triggering the death of motor neurons.


Type: Small Molecule
Stage: Phase III
Status: Completed
Sponsor: Teva Pharmaceutical Industries

TDI Says:

Based on clinical trial results, we think talampanel is unlikely to be of benefit to people with ALS.

Published Results

Comment on this Topic

(All comments are moderated before they appear here.)